U.S. Markets open in 4 hrs 5 mins

Endo International plc (ENDP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.12+0.23 (+1.78%)
At close: 4:00PM EDT
People also watch
VRXMYLPRGOALXNHZNP
Interactive chart
Previous Close12.89
Open12.94
Bid12.00 x 300
Ask13.80 x 200
Day's Range12.89 - 13.45
52 Week Range9.70 - 24.93
Volume3,750,619
Avg. Volume9,105,055
Market Cap2.93B
Beta-0.28
PE Ratio (TTM)-0.86
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts
    Investor's Business Daily5 days ago

    Teva Pharma, Eagle Pharma, Depomed Among Slew Getting Price Haircuts

    Depomed and Eagle stocks plunged Thursday after a Mizuho analyst slashed her price targets on a slew of drugmakers.

  • Barrons.com11 days ago

    Valeant Pharmaceuticals: Intrigued…Really?

    This very blog has offered up no shortage of opinions on shares Valeant Pharmaceuticals International (VRX)...some good, some bad and some still undecided. Quoting from Gilbert’s recent note, StreetInsider reported: We have been cautious/skeptical on VRX for a very long time, and uncertainties around the growth potential and durability of key franchises, the potential cost of past sins, and the heavy debt load have kept us at Hold.

  • American City Business Journals14 days ago

    BDSI CEO on Belbuca revenue potential: We're on an upward trend

    After reacquiring the license to pain management product Belbuca from Endo Pharmaceuticals earlier this year , Raleigh’s BioDelivery Sciences International (BDSI) is reaping the benefits. The company reported net revenue of $29.5 million for the first quarter of 2017, compared to net revenue of $3 million for the first quarter of 2016. Net revenue for the first quarter of this year included net sales of Belbuca of $4.6 million – as compared to what would have been $640,000 in royalties without the reacquisition – and $20 million in contract revenues “related to the release of deferred revenue for Belbuca,” according to BDSI.